THE CASE
Scientific discoveries can often take a substantial amount of time, effort and resources to materialise into impactful innovations. By using advanced Artificial Intelligence (AI), the EVA project aims to speed up how we gather evidence and find the most promising areas to research. Tailored for the Life Science industry, the project is creating clear, trustworthy, and evidence-based AI tools. From accelerating drug development to identifying potential side effects earlier, EVA could mean new medications reaching patients sooner and safer treatments becoming the norm. By focusing on real-world challenges faced by scientists, researchers and healthcare professionals, EVA is developing and testing three AI tools that could transform our scientific approach.
The partnership behind the project consists of the Danish Medicines Council, KIOX, the University of Southern Denmark (SDU) and the University of Ghent (UGhent), Leo Pharma and Nordic Healthcare Group.
Picture credit:
wix.com
THE COLLABORATION
Transforming the concept and impact of AI-powered research and innovation requires the right narrative. From the very start, G2G worked closely with the consortium to develop a project plan that shows clear, quantifiable impact and breakthrough potential. Our financial expertise ensured a well-balanced budget that met program requirements, while our strategic planning helped partners align their contributions with project timelines.
We oversaw the grant preparation phase, making sure that EVA was fully prepared to move from funding approval to real impact in Life Sciences. During the project, our team is supporting with general project management activities. We are beyond excited to be able to follow the project as it progresses and impacts the future of healthcare!